Cardiff Oncology (CRDF) Depreciation & Amortization (CF) (2016 - 2025)
Cardiff Oncology (CRDF) has disclosed Depreciation & Amortization (CF) for 15 consecutive years, with $88000.0 as the latest value for Q4 2025.
- Quarterly Depreciation & Amortization (CF) fell 8.33% to $88000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $364000.0 through Dec 2025, down 9.9% year-over-year, with the annual reading at $364000.0 for FY2025, 9.9% down from the prior year.
- Depreciation & Amortization (CF) hit $88000.0 in Q4 2025 for Cardiff Oncology, down from $89000.0 in the prior quarter.
- In the past five years, Depreciation & Amortization (CF) ranged from a high of $119000.0 in Q1 2021 to a low of $31000.0 in Q1 2022.
- Historically, Depreciation & Amortization (CF) has averaged $92650.0 across 5 years, with a median of $97000.0 in 2023.
- Biggest five-year swings in Depreciation & Amortization (CF): tumbled 73.95% in 2022 and later soared 190.32% in 2023.
- Year by year, Depreciation & Amortization (CF) stood at $113000.0 in 2021, then dropped by 23.89% to $86000.0 in 2022, then grew by 19.77% to $103000.0 in 2023, then decreased by 6.8% to $96000.0 in 2024, then fell by 8.33% to $88000.0 in 2025.
- Business Quant data shows Depreciation & Amortization (CF) for CRDF at $88000.0 in Q4 2025, $89000.0 in Q3 2025, and $94000.0 in Q2 2025.